Fig. 4: DoriVac induces enhanced Th1 CD4+ T cell activation in mice.
a, IFNγ ELISpot showing frequency of antigen-specific T cells in splenocytes on day 35 (n = 4) after treatment with DoriVac compared with the bolus vaccine. b, Quantification of IFNγ ELISpot spot forming units (SFUs, n = 4) shows significant increase in SARS-COV-2 antigen-specific T cell frequency after treatment with DoriVac compared with the bolus vaccine and negative control (that is, untreated). c, Percentages of CD4+ CD107a+ T cells in the LN (n = 4) as determined by flow cytometry and representative flow plots on day 35. d, Percentages of the LN CD4+ PD-1+ population (n = 4) as determined by flow cytometry on day 21. e, Percentages of LN CD4+ Treg population (n = 4) as determined by flow cytometry on day 21. f, IFNγ ELISpot showing frequency of CD4+ enriched antigen-specific splenocytes (n = 4, day 35) after treatment with SARS-CoV-2-HR2 DoriVac. g, Corresponding quantification of IFNγ ELISpot SFUs (n = 4). Data are represented as mean ± s.d. The ELIspot data in b were analysed by two-way ANOVA (with correction for multiple comparisons using Tukey’s test). The ELISpot data in g were analysed by one-way ANOVA (with correction for multiple comparisons using Tukey’s test). In both analyses, statistical significance was defined as a multiplicity-adjusted P value less than 0.05. The flow data were analysed by multiple unpaired t-tests, and significance was defined as a two-tailed P value less than 0.05. *P ≤ 0.05; **P ≤ 0.01; bars without asterisks indicate no statistically significant difference (P > 0.05). Unless otherwise indicated, n refers to biologically independent mice.
